Catherine S. Marshall
5 Papers
3 Citations
Catherine S. Marshall is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Hepatitis C. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb.
Joshua S. Davis,Joshua S. Davis,C. Mackrow,Paula Binks,W. Fletcher,Pascale Dettwiller,Catherine S. Marshall,Julie Day,W. Pratt,Steven Y. C. Tong,Steven Y. C. Tong +10 more
TL;DR: This trial demonstrated no significant benefit of adjunctive ibuprofen in adults with uncomplicated cellulitis, and the trial was powered to detect a large effect, and hence it is unclear whether the 15% absolute increase in the primary end point in the ib uprofen group was attributable to chance.
20
Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled Trial.
Joshua S. Davis,Joshua S. Davis,Michelle D. Young,Catherine S. Marshall,J. Tate-Baker,M. Madison,Sathyam Sharma,C. Silva,Tracey L. Jones,Jane Davies +9 more
TL;DR: On-treatment monitoring with blood tests and clinic visits may not be necessary during sofosbuvir-based HCV treatment in selected patients.
Viral hepatitis in correctional facilities in the Northern Territory of Australia 2003-2017.
Richard P. Sullivan,Robert W. Baird,Kevin Freeman,Hugh Heggie,Joshua S. Davis,Joshua S. Davis,Catherine S. Marshall,Jane Davies +7 more
TL;DR: This paper reviewed serological results and testing rates for hepatitis B and hepatitis C performed in correctional facilities in the Northern Territory of Australia between July 1st, 2003 and June 30th, 2017.
The unique aspects of chronic hepatitis B infection in Aboriginal and Torres Strait Islander people
TL;DR: The findings suggest that Australian junior doctors focus on pharmacological treatments and oxygen for refractory breathlessness, and they have less awareness of the evidence-based, multidisciplinary, non-pharmacological interventions, which come first in clinical practice.
1
The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study.
Emma J. Bishop,Ravindranath Tiruvoipati,Julie Metcalfe,Catherine S. Marshall,John Botha,Peter G. Kelley +5 more
TL;DR: Tigecycline is a third‐line therapy for severe Clostridium difficile infection in Australasian guidelines, but differences in strain types make it difficult to extrapolate international tigecYcline efficacy data with combination or monotherapy to Australian practice, where experience is limited.